With the acquisition of Amplitude Vascular Systems announced recently, Stryker joins the IVL technology race with Johnson & Johnson and Boston Scientific.

Industry analysts noted cardiovascular quickly emerging as an increased area of focus for Stryker, which has prioritized acquisitions and shifting into higher growth markets with other leading device makers. This latest announcement follows the company’s 2025 purchase of Inari Medical and related vascular sector acquisitions by Boston Scientific in 2025 and Johnson & Johnson in 2024.

“This acquisition represents an important step in advancing our vision to build a comprehensive peripheral vascular platform and address significant unmet clinical needs,” said Stryker Chairman and CEO Kevin Lobo. “Combining this innovation with Stryker’s scale and clinical expertise, we believe we can help expand treatment options for physicians and improve care for patients with calcified peripheral arterial disease.”

IVL is a fast-growing technology in cardiovascular intervention and is used to treat calcified peripheral and coronary lesions, and Stryker expects the acquisition to strengthen its Peripheral Vascular (PV) portfolio by adding revascularization technology as physicians adopt IVL-based calcium modification in complex procedures.

AVS’ technology is designed to use pulsed CO₂-generated pressure waves uniformly delivered through an IVL balloon catheter, to fracture calcium and optimize luminal gain. The platform is designed to enhance catheter deliverability, treatment speed and therapy efficiency. Once cleared for use in applicable markets, the product will complement Stryker’s existing PV offerings and support the company’s strategy to expand its presence in arterial disease treatment.